What question did this study set out to answer?

To review emerging strategies, preclinical assays, and screening models for novel psychedelic analogues while providing guidance for next-generation neuropsychiatric drug development.

September 17, 2026ACS Chemical NeuroscienceOpen Access

Next-Generation Psychedelic Drug Development

View Full Paper

Ask AI

Bookmark

To review emerging strategies, preclinical assays, and screening models for novel psychedelic analogues while providing guidance for next-generation neuropsychiatric drug development.
Synthesized literature on novel psychedelic analogues and emerging therapeutic regimens for psychiatric disorders.
Evaluated the methodological strengths, translational validity, and limitations of existing in vitro and in vivo screening assays.
Identified translational limitations in conventional assays used to evaluate psychedelic mechanisms, subjective effects, and non-hallucinogenic therapeutic properties.
Formulated strategic considerations to optimize variable control, safety assessments, and molecular screening for future psychedelic therapeutics.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review highlights preclinical models and screening assays for psychedelic analogues in neuropsychiatric disorders, suggesting standardized frameworks to guide next-generation therapies.

Cite This Study

Cameron et al. (2026) studied this question.

synapsesocial.com/papers/6aabb7a65f706d05830e6d16 https://doi.org/10.1021/acschemneuro.6c00492

View Full Paper

Ask AI

Bookmark

Implication

Review highlights preclinical models and screening assays for psychedelic analogues in neuropsychiatric disorders, suggesting standardized frameworks to guide next-generation therapies.

Next-Generation Psychedelic Drug Development

Key Points

Discussion

Implication

Cite This Study

Next-Generation Psychedelic Drug Development

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider